<DOC>
	<DOCNO>NCT00262860</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together gemcitabine hydrochloride may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together gemcitabine hydrochloride work treat patient relapsed refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Bortezomib Gemcitabine Hydrochloride Treating Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate ( partial complete response ) patient relapse refractory Hodgkin 's lymphoma treat bortezomib gemcitabine hydrochloride . Secondary - Determine safety toxic effect regimen patient . - Determine time progression patient treat regimen . - Correlate NF-kB inhibition proteasome activity response patient treat regimen . OUTLINE : This multicenter , pilot study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year annually thereafter . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma Recurrent refractory disease prior standard combination chemotherapy Measurable disease , define ≥ 1 unidimensionally measurable lesion &gt; 1 cm physical exam image study No history nonHodgkin 's lymphoma No history hematological malignancy PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,000/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) ( unless due Gilbert 's disease involvement Hodgkin 's lymphoma ) AST ≤ 3 time ULN ( unless due involvement Hodgkin 's lymphoma ) Renal Creatinine clearance ≥ 30 mL/min Cardiovascular Ejection fraction ≥ 40 % MUGA echocardiogram ( patient history cardiac disease ) Pulmonary Must require supplemental oxygen therapy Immunologic No known HIV infection No uncontrolled bacterial , viral , fungal infection Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy require therapy No peripheral neuropathy ≥ grade 2 within past 14 day No hypersensitivity boron No hypersensitivity mannitol PRIOR CONCURRENT THERAPY : Biologic therapy More 30 day since prior monoclonal antibody therapy Hodgkin 's lymphoma More 6 month since prior autologous stem cell transplantation No prior allogeneic stem cell transplantation No concurrent sargramostim ( GMCSF ) No concurrent pegfilgrastim filgrastim ( GCSF ) No concurrent interleukin11 ( oprelvekin ) Chemotherapy See Disease Characteristics More 30 day since prior chemotherapy Hodgkin 's lymphoma No prior treatment gemcitabine hydrochloride Endocrine therapy More 30 day since prior corticosteroid therapy Hodgkin 's lymphoma No concurrent corticosteroid therapy Radiotherapy More 30 day since prior radiotherapy Hodgkin 's lymphoma Other No prior treatment bortezomib More 14 day since prior investigational drug No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>